AWM
CMPX icon

Apollon Wealth Management’s Compass Therapeutics CMPX Stock Holding History

Apollon Wealth Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.1K Buy
+19,687
New +$58.1K ﹤0.01% 1554
2025
Q4 		– Sell
-10,015
Closed -$35.1K – 1321
2025
Q3 		$35.1K Buy
+10,015
New +$31.6K ﹤0.01% 1307

Other funds holding CMPX

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
AA
ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return
WCP
Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

Apollon Wealth Management's CMPX Position: Q2 2026 in Review

Apollon Wealth Management opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 19,687 shares worth $43.1K. The stake represents ﹤0.01% of the portfolio and ranks #1554 among its holdings. This is a return to the name: Apollon Wealth Management previously reported a position in CMPX as recently as Q3 2025.

Apollon Wealth Management first reported a position in CMPX in Q3 2025 and has held it in 2 quarters since. 21 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Apollon Wealth Management held 19,687 shares of Compass Therapeutics worth $43.1K as of Q2 2026.
  • Compass Therapeutics was a new Apollon Wealth Management position in Q2 2026.
  • Compass Therapeutics made up ﹤0.01% of Apollon Wealth Management's portfolio in Q2 2026, its #1554 holding.
  • Apollon Wealth Management first reported a position in Compass Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 21 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Apollon Wealth Management's 13F filing for Q2 2026, filed 23 Jul 2026.